Anixa Biosciences IncNASDAQ:ANIX
- LAST PRICE3.3200
- TODAY'S CHANGE (%)0.1000 (3.1056%)
- Bid / Lots3.2200/ 93
- Ask / Lots3.5500/ 1
- Open / Previous Close3.3700 / 3.2200
- Day Range
- 52 Week Range
- Volume68,771
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ANIX |
|---|---|---|
| 09:32 ET | 2679 | 3.425 |
| 09:33 ET | 503 | 3.435 |
| 09:35 ET | 1500 | 3.3245 |
| 09:39 ET | 400 | 3.32 |
| 09:50 ET | 2550 | 3.37 |
| 09:51 ET | 900 | 3.37 |
| 09:55 ET | 500 | 3.389 |
| 10:00 ET | 200 | 3.39 |
| 10:06 ET | 100 | 3.39 |
| 10:09 ET | 300 | 3.365 |
| 10:18 ET | 5578 | 3.385 |
| 10:20 ET | 300 | 3.42 |
| 10:22 ET | 100 | 3.3646 |
| 10:26 ET | 1100 | 3.42 |
| 10:31 ET | 1800 | 3.3906 |
| 10:33 ET | 100 | 3.42 |
| 10:38 ET | 100 | 3.41 |
| 10:44 ET | 100 | 3.41 |
| 10:51 ET | 200 | 3.4299 |
| 10:56 ET | 100 | 3.43 |
| 11:00 ET | 100 | 3.41 |
| 11:05 ET | 569 | 3.41 |
| 11:12 ET | 200 | 3.385 |
| 11:14 ET | 100 | 3.4 |
| 11:16 ET | 127 | 3.4 |
| 11:18 ET | 408 | 3.4 |
| 11:34 ET | 100 | 3.42 |
| 11:54 ET | 300 | 3.395 |
| 12:03 ET | 290 | 3.3565 |
| 12:06 ET | 1204 | 3.36 |
| 12:08 ET | 120 | 3.38 |
| 12:30 ET | 100 | 3.3456 |
| 12:33 ET | 100 | 3.3799 |
| 12:42 ET | 100 | 3.38 |
| 12:44 ET | 900 | 3.38 |
| 12:48 ET | 200 | 3.3789 |
| 12:53 ET | 100 | 3.35 |
| 12:55 ET | 400 | 3.35 |
| 01:09 ET | 824 | 3.362 |
| 01:15 ET | 599 | 3.34 |
| 01:33 ET | 100 | 3.36 |
| 01:56 ET | 100 | 3.36 |
| 01:58 ET | 100 | 3.33 |
| 02:03 ET | 1838 | 3.3301 |
| 02:20 ET | 100 | 3.33 |
| 02:41 ET | 100 | 3.35 |
| 02:45 ET | 200 | 3.33 |
| 02:59 ET | 1163 | 3.3108 |
| 03:26 ET | 9400 | 3.3094 |
| 03:35 ET | 120 | 3.2896 |
| 03:44 ET | 9527 | 3.31 |
| 03:46 ET | 733 | 3.29 |
| 03:51 ET | 100 | 3.31 |
| 03:57 ET | 100 | 3.34 |
| 04:00 ET | 4498 | 3.32 |
Nov 22, 2024
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset, from 8:15AM ET on Friday Nov 22, 2024 by Dow Jones
8:15AM ET on Friday Nov 22, 2024 by Dow Jones
Nov 19, 2024
DJ Anixa Biosciences Is Maintained at Buy by D. Boral Capital, from 12:59PM ET on Tuesday Nov 19, 2024 by Dow Jones
12:59PM ET on Tuesday Nov 19, 2024 by Dow JonesDJ Anixa Biosciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co., from 6:36AM ET on Tuesday Nov 19, 2024 by Dow Jones
6:36AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 18, 2024
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial, from 8:20AM ET on Monday Nov 18, 2024 by Dow Jones
8:20AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 12, 2024
Sidoti Events, LLC's Virtual November Micro-Cap Conference, from 8:31AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:31AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Anixa Biosciences Inc | 103.0M | -8.5x | --- |
Context Therapeutics Inc | 104.2M | -1.6x | --- |
Fractyl Health Inc | 100.5M | -1.5x | --- |
CAMP4 Therapeutics Corp | 105.5M | -1.9x | --- |
Tiziana Life Sciences Ltd | 105.4M | -5.5x | --- |
Monopar Therapeutics Inc | 106.1M | -9.8x | --- |
Company Information
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
Contact Information
- Headquarters
- 3150 Almaden Expy Ste 250SAN JOSE, CA, United States 95118
- Phone
- 408-708-9808
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Amit Kumar
- President, Chief Financial Officer, Chief Operating Officer, Company Secretary
- Michael Catelani
- Lead Independent Director
- Lewis Titterton
- Independent Director
- Arnold Baskies
- Independent Director
- Emily Gottschalk
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $103.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.83 |
EPS | $-0.39 |
Book Value | $0.78 |
P/E Ratio | -8.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
